Login / Signup

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).

Derrick Ho Wai SiuNiall TebbuttLorraine ChantrillChris KarapetisChristopher SteerKate WilsonDavid EspinozaLisa BaileySonia YipJeff CuffNick PavlakisSubotheni ThavaneswaranKaren BriscoeRatnesh SrivastavJennifer ShannonEva SegelovJeannie TieSusan CairdAlessandra FrancesconiTimothy PriceMelanie WuttkeRahul LadwaKatrin SjoquistMatthew Burge
Published in: BMC cancer (2021)
Australia New Zealand Clinical Trials Registry: ACTRN12618000233224 , prospectively registered 14 February 2018.
Keyphrases
  • metastatic colorectal cancer
  • phase ii study
  • open label
  • clinical trial
  • phase ii
  • phase iii
  • wild type
  • study protocol
  • double blind
  • placebo controlled
  • locally advanced
  • randomized controlled trial
  • combination therapy